Valneva SE's Corporate Developments and Shareholder Meeting Insights

Author: Kelly Martin Updated: 06-04-2025 01:15 AM

Valneva SE Shares Key Insights on Upcoming Shareholder Meeting

Saint-Herblain, France – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) is a company recognized for its innovative contributions to the vaccine industry. The Company is gearing up for its Combined General Meeting, scheduled for June 25, 2025. This forthcoming meeting plays a pivotal role for shareholders in understanding the Company's direction and performance.

Documentation for the General Meeting Now Available

The Preliminary Notice of Meeting has been officially published, providing details such as the agenda, proposed resolutions, and accompanying guidelines for participation and voting. This notice appeared in the Bulletin des Annonces Légales Obligatoires, ensuring that all shareholders are well-informed.

Shareholders can easily access all necessary documents related to the meeting on Valneva's official website. Those interested in receiving Meeting materials via mail or e-mail are encouraged to reach out to the Company within a set timeframe, as specified in the applicable regulations.

Leadership Transition and Corporate Highlights

In a notable update, Valneva has announced that Mr. Franck Grimaud, a co-founder and the Chief Business Officer, will be departing the Company following the meeting on June 25. Over his 26-year tenure, Franck has significantly influenced Valneva's strategy and commercial vaccine business.

CEO Thomas Lingelbach expressed appreciation for Franck's contributions and wished him well in future endeavors, highlighting the collaborative spirit that has characterized Valneva's journey.

About Valneva SE

Valneva SE is at the forefront of vaccine development, focusing on creating, manufacturing, and marketing prophylactic vaccines tailored to address urgent healthcare needs. Their method involves a specialized, strategic approach to vaccine development, utilizing extensive knowledge across various modalities.

The Company has successfully transitioned several vaccines from initial research to market approval, boasting a current portfolio that includes three unique travel vaccines. Revenues from these offerings fuel the ongoing development of innovative vaccines, including the only Lyme disease candidate in advanced clinical stages, in partnership with Pfizer, alongside other significant vaccine candidates targeting public health challenges such as Zika and Shigella.

Valneva Investor and Media Contacts

Investors and media representatives seeking further information can reach out to: Laetitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelot-fontaine@valneva.com

Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Frequently Asked Questions

What is the purpose of the Combined General Meeting?

The Meeting aims to discuss the Company's governance, proposed resolutions, and provide shareholders with updates on Valneva's business strategies.

When will the Combined General Meeting take place?

The Meeting is scheduled for June 25, 2025, at 2:00 p.m. CEST.

How can shareholders access Meeting documents?

Shareholders can access all necessary Meeting materials on Valneva's official website and may request physical copies via email.

Who is leaving Valneva SE and why?

Mr. Franck Grimaud, co-founder and Chief Business Officer, is departing after a long tenure to pursue new opportunities.

What innovative products does Valneva SE offer?

Valneva specializes in developing vaccines for infectious diseases, including proprietary vaccines for travel diseases and a Lyme disease vaccine currently in advanced development.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.